Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of ...
Ingenix, the AI and biology company built around a single question - "What would it take for AI to truly understand biology?" - has today announced a €13m seed-extension funding round led by Sofinnova ...
The rapid expansion of complex biotherapeutic modalities—including oligonucleotides, mRNA, and antibody-drug conjugates—is ...
Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...
Keep learning. Excel in your career. Choose from more than 200 courses in seven different categories, taught by experts in the chemistry community, online and in person.
Goldman Sachs’ Ziyi breaks down why China is becoming the go-to market for early-stage drug development from cheaper, faster trials to an edge in engineering-driven ‘modalities’; even as the country ...
The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...
Drug discovery is entering a new phase of complexity. From peptides and oligonucleotides to targeted protein degraders and other emerging modalities, many of today’s therapies require advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results